ArticleRedox biology2026
Low serum selenium combined with SELENOP-autoantibodies are associated with persistent fatigue after SARS-CoV-2 infection.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytokines found during post-acute sequelae after COVID-19 are known to reduce selenoprotein biosynthesis, raising the question whether low selenium, impaired selenoprotein P (SELENOP) production, and autoantibodies to SELENOP (SELENOP-aAb) are associated with persistent fatigue after SARS-CoV-2 infection.
methodsPersistent symptoms and selenium determinants were assessed on average 21.9 months after a PCR-verified SARS-CoV-2 infection in a cross-sectional population-based study (n = 750 adults, 54.1% female). Study participants were categorized based on the presence of low selenium levels (<70 μg/L), low SELENOP levels (<4.1 mg/L), and SELENOP-aAb positivity (≥3.0 BI). Regression models were fitted to assess associations between selenium determinants and persistent fatigue, adjusted for potential confounders.
findingsPersistent fatigue was self-reported by 23.1% (n = 173) of participants. Low serum selenium was measured in 63.7% (n = 478), low SELENOP in 89.6% (n = 672), and elevated SELENOP-aAb in 3.9% (n = 29). A combination of low selenium and elevated SELENOP-aAb was found in 1.9% (n = 14) participants, a combination of low SELENOP and SELENOP-aAb in 3.2% (n = 24). Individually, all three selenium-related determinants showed no strong indication for an association with persistent fatigue. However, the combination of selenium deficiency and SELENOP-aAb positivity showed a prevalence ratio of 2.16 (95%-CI: 1.13-4.11), and the combination of SELENOP deficiency and SELENOP-aAb positivity a prevalence ratio of 2.15 (95% Cl: 1.01; 4.60) compared to the reference group.
interpretationThe study indicates that in a fraction of COVID-19 affected participants low selenium/SELENOP levels in combination with SELENOP-specific autoantibodies are associated with a two times higher prevalence of persistent fatigue after SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.